tanshinone ii a has been researched along with chlorogenic acid in 3 studies
| Studies (tanshinone ii a) | Trials (tanshinone ii a) | Recent Studies (post-2010) (tanshinone ii a) | Studies (chlorogenic acid) | Trials (chlorogenic acid) | Recent Studies (post-2010) (chlorogenic acid) |
|---|---|---|---|---|---|
| 61 | 0 | 41 | 3,276 | 76 | 2,241 |
| Protein | Taxonomy | tanshinone ii a (IC50) | chlorogenic acid (IC50) |
|---|---|---|---|
| Aldo-keto reductase family 1 member B10 | Homo sapiens (human) | 7.9 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 0.95 | |
| Aldo-keto reductase family 1 member B1 | Homo sapiens (human) | 1.05 | |
| Tyrosine-protein phosphatase non-receptor type 1 | Homo sapiens (human) | 0.1 | |
| large T antigen | Betapolyomavirus macacae | 14.67 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Barlow, D; Hylands, P; Naeem, S | 1 |
| Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P | 1 |
| Chen, J; Gao, K; Huang, F; Tepe, JJ; Wang, R; Wei, GW | 1 |
3 other study(ies) available for tanshinone ii a and chlorogenic acid
| Article | Year |
|---|---|
Construction of an Indonesian herbal constituents database and its use in Random Forest modelling in a search for inhibitors of aldose reductase.
Topics: Aldehyde Reductase; Artificial Intelligence; Computer Simulation; Databases, Factual; Drug Design; Enzyme Inhibitors; Humans; Indonesia; Models, Biological; Plants, Medicinal; Software | 2012 |
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship | 2012 |
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
Topics: Antiviral Agents; Coronavirus 3C Proteases; Humans; Protease Inhibitors | 2021 |